Payer Communications Safe Harbor Should Extend To Off-Label Uses – Industry
Executive Summary
US FDA should apply same regulatory protections to manufacturer communications with payers about unapproved uses that agency draft guidance provides to information exchanges about investigational products, biopharma companies say.